JP2024511449A - Ｋｖ１．３遮断薬 - Google Patents

Ｋｖ１．３遮断薬 Download PDF

Info

Publication number
JP2024511449A
JP2024511449A JP2023558496A JP2023558496A JP2024511449A JP 2024511449 A JP2024511449 A JP 2024511449A JP 2023558496 A JP2023558496 A JP 2023558496A JP 2023558496 A JP2023558496 A JP 2023558496A JP 2024511449 A JP2024511449 A JP 2024511449A
Authority
JP
Japan
Prior art keywords
amino acid
seq
ion channel
side chain
channel blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511449A5 (enExample
Inventor
ヘンリク フィスカー ムンク
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2024511449A publication Critical patent/JP2024511449A/ja
Publication of JP2024511449A5 publication Critical patent/JP2024511449A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023558496A 2021-03-23 2022-03-22 Ｋｖ１．３遮断薬 Pending JP2024511449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21164384.6 2021-03-23
EP21213431 2021-12-09
EP21213431.6 2021-12-09
PCT/EP2022/057533 WO2022200374A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Publications (2)

Publication Number Publication Date
JP2024511449A true JP2024511449A (ja) 2024-03-13
JP2024511449A5 JP2024511449A5 (enExample) 2025-03-27

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558496A Pending JP2024511449A (ja) 2021-03-23 2022-03-22 Ｋｖ１．３遮断薬

Country Status (12)

Country Link
US (1) US20240182531A1 (enExample)
EP (1) EP4314024A1 (enExample)
JP (1) JP2024511449A (enExample)
KR (1) KR20230159403A (enExample)
AU (1) AU2022245193A1 (enExample)
BR (1) BR112023019022A2 (enExample)
CA (1) CA3208713A1 (enExample)
CL (1) CL2023002590A1 (enExample)
IL (1) IL305219A (enExample)
MX (1) MX2023010930A (enExample)
TW (1) TW202304957A (enExample)
WO (1) WO2022200374A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
WO2021053194A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
WO2021053194A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers

Also Published As

Publication number Publication date
US20240182531A1 (en) 2024-06-06
CA3208713A1 (en) 2022-09-29
EP4314024A1 (en) 2024-02-07
CL2023002590A1 (es) 2024-03-15
AU2022245193A1 (en) 2023-09-07
IL305219A (en) 2023-10-01
BR112023019022A2 (pt) 2023-10-17
WO2022200374A1 (en) 2022-09-29
KR20230159403A (ko) 2023-11-21
TW202304957A (zh) 2023-02-01
MX2023010930A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7703520B2 (ja) Ｋｖ１．３遮断剤
US10905745B2 (en) Acylated GLP-1/GLP-2 dual agonists
KR102587196B1 (ko) Glp-1/glp-2 이중 효능제
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
KR20260038313A (ko) 글리피칸-3을 표적화하는 펩티드 조성물 및 그의 용도
US20240182531A1 (en) KV1.3 Blockers
RU2825633C1 (ru) БЛОКАТОРЫ Kv1.3
CN117255798A (zh) Kv1.3阻断剂
JP2025534884A (ja) 阻害剤
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260407